BioAcyl Corp
BioAcyl Corp |
|
 |
 |
 |
|
Kaur, S., & Roberts, D. D. (2024). Emerging functions of thrombospondin-1 in immunity. Seminars in Cell & Developmental Biology, 155, 22–31. Added by: Dr. Enrique Feoli (09/03/2026, 11:59) Last edited by: Dr. Enrique Feoli (09/03/2026, 12:09) |
 |
| Resource type: Journal Article DOI: 10.1016/j.semcdb.2023.05.008 ID no. (ISBN etc.): 1084-9521 BibTeX citation key: Kaur2024 View all bibliographic details  |
Categories: BioAcyl Corp Subcategories: Thrombospodin-1 Keywords: Antigen presenting cells, Antitumor immunity, autoimmune disease, CD47, natural killer cells, T cells Creators: Kaur, Roberts Collection: Seminars in Cell & Developmental Biology |
Views: 5/14
|
| Abstract |
|
Thrombospondin-1 is a secreted matricellular glycoprotein that modulates cell behavior by interacting with components of the extracellular matrix and with several cell surface receptors. Its presence in the extracellular matrix is induced by injuries that cause thrombospondin-1 release from platelets and conditions including hyperglycemia, ischemia, and aging that stimulate its expression by many cell types. Conversely, rapid receptor-mediated clearance of thrombospondin-1 from the extracellular space limits its sustained presence in the extracellular space and maintains sub-nanomolar physiological concentrations in blood plasma. Roles for thrombospondin-1 signaling, mediated by specific cellular receptors or by activation of latent TGFβ, have been defined in T and B lymphocytes, natural killer cells, macrophages, neutrophils, and dendritic cells. In addition to regulating physiological nitric oxide signaling and responses of cells to stress, studies in mice lacking thrombospondin-1 or its receptors have revealed important roles for thrombospondin-1 in regulating immune responses in infectious and autoimmune diseases and antitumor immunity.
Added by: Dr. Enrique Feoli Last edited by: Dr. Enrique Feoli |
| Notes |
|
Cytotoxic T cell supramolecular attack particles (SMAPs) Cytotoxic T lymphocytes (CTLs) defend against viral and bacterial infections and can eliminate malignant cells that express recognized neoantigens [83], [84]. Activated CTLs release granzymes and the pore-forming protein perforin-1 (Prf1) at the immune synapse, which mediate killing of target cells [85], [86], [87]. SMAPs that contain granzymes, Prf1 and TSP1 were recently identified that are released by CTLs and lack a phospholipid membrane [88]. SMAPs may provide a more sustained cytotoxic activity that complements the acute function of soluble granzyme B released by CTLs [89]. SMAPs are produced cell autonomously and are taken up by target cells via unknown mechanisms. Mass spectrometry identified a C-terminal ∼60 kDa fragment of TSP1 in SMAPs, which may engage multiple receptor such as CD36, CD47 and integrins. Further studies are needed to determine whether this fragment is a new splice isoform or a proteolytic fragment of TSP1 and to address the function of TSP1 in SMAPs biogenesis and in target cell recognition. Added by: Dr. Enrique Feoli Last edited by: Dr. Enrique Feoli |
